Ion channel gene therapy for smooth muscle disorders: Relaxing smooth muscles to treat erectile dysfunction

Assay and Drug Development Technologies

Volumn 4, Issue 1, 2006, Pages 89-95

  Schiff, Jonathan D ^a   Melman, Arnold ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL; CHLORIDE CHANNEL; ION CHANNEL; PLASMID DNA; POTASSIUM CHANNEL; SODIUM CHANNEL;

APOPTOSIS; CALCIUM TRANSPORT; CELL PROLIFERATION; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; ERECTILE DYSFUNCTION; GENE THERAPY; GENE TRANSFER; HISTOPATHOLOGY; HUMAN; HYPERPOLARIZATION; IN VIVO STUDY; IRRITABLE COLON; MORBIDITY; MUSCLE DISEASE; MUSCLE RELAXATION; NONHUMAN; OVERACTIVE BLADDER; PLASMID VECTOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOOTH MUSCLE; SMOOTH MUSCLE FIBER; SMOOTH MUSCLE RELAXATION; TARGET CELL;

BASE SEQUENCE; GENE THERAPY; HUMANS; IMPOTENCE; LARGE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNEL ALPHA SUBUNITS; MALE; MOLECULAR SEQUENCE DATA; MUSCLE, SMOOTH; PHOSPHODIESTERASE INHIBITORS; PROMOTER REGIONS (GENETICS); VASODILATOR AGENTS;

EID: 33645321398     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/adt.2006.4.89     Document Type: Conference Paper

References (30)

1. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA: Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998;338:1397-1404.
2. Padma-Nathan H, Steers WD, Wicker PA: Efficacy and safety of oral sildenafil in the treatment of erectile dysfunction: a double-blind, placebo-controlled study of 329 patients. Sildenafil Study Group. Int J Clin Pract 1998;52:375-379.
3. Virag R: Intracavernous injection of papaverine for erectile failure. Lancet 1982;2:938.
4. The long-term safety of alprostadil (prostaglandin-E1) in patients with erectile dysfunction. The European Alprostadil Study Group. Br J Urol 1998;82:538-543.
5. Ishii N, Watanabe H, Irisawa C, Kikuchi Y, Kubota Y, Kawamura S, Suzuki K, Chiba R, Tokiwa M, Shirai M: Intracavernous injection of prostaglandin E1 for the treatment of erectile impotence. J Urol 1989;141:323-325.
6. Kunelius P, Lukkarinen O: Intracavernous self-injection of prostaglandin E1 in the treatment of erectile dysfunction. Int J Impot Res 1999;11:21-24.
7. Lea AP, Bryson HM, Balfour JA: Intracavernous alprostadil. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in erectile dysfunction. Drugs Aging 1996;8:56-74.
8. Stief CG: Phosphodiesterase inhibitors in the treatment of erectile dysfunction. Drugs Today (Barc) 2000;36:93-99.
9. Gresser U, Gleiter CH: Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil - review of the literature. Eur J Med Res 2002;7:435-446.
10. Pomeranz HD, Bhavsar AR: Nonarteritic ischemic optic neuropathy developing soon after use of sildenafil (Viagra): a report of seven new cases. J Neuroophthalmol 2005;25:9-13.
11. Benson GS, Boileau MA: The penis. In: Sexual Function and Dysfunction in Adult and Pediatric Urology, 4th ed. (Gillenwater JY, Grayhack JT, Howards SS, Mitchell ME, eds.), pp. 1935-1974. Lippincott Williams & Wilkins, New York,2002.
12. Moreno AP, Campos de Carvalho AC, Christ G, Melman A, Spray DC: Gap junctions between human corpus cavernosum smooth muscle cells: gating properties and unitary conductance. Am J Physiol 1993;264:C80-C92.
13. Gaspar HB, Parsley KL, Howe S, King D, Gilmour KC, Sinclair J, Brouns G, Schmidt M, Von Kalle C, Barington T, Jakobsen MA, Christensen HO, Al Ghonaium A, White HN, Smith JL, Levinsky RJ, Ali RR, Kinnon C, Thrasher AJ: Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 2004;364:2181-2187.
14. Rolland A: Gene medicines: the end of the beginning? Adv Drug Deliv Rev 2005;57:669-73.
15. Rogers RS, Graziottin TM, Lin CS, Kan YW, Lue TF: Intracavernosal vascular endothelial growth factor (VEGF) injection and adeno-associated virus-mediated VEGF gene therapy prevent and reverse venogenic erectile dysfunction in rats. Int J Impot Res 2003;15:26-37.
16. Chancellor MB, Tirney S, Mattes CE, Tzeng E, Birder LA, kanai AJ, de Groat WC, Huard J, Yoshimura N: Nitric oxide synthase gene transfer for erectile dysfunction in a rat model. BJU Int 2003;91:691-696.
17. Champion HC, Bivalacqua TJ, Hyman AL, Ignarro LJ, Hellstrom WJ, Kadowitz PJ: Gene transfer of endothelial nitric oxide synthase to the penis augments erectile responses in the aged rat. Proc Natl Acad Sci U S A 1999;96:11648-11652.
18. Garban H, Marquez D, Magee T, MoodyJ, Rajavashisth T, Rodriguez JA, Hung A, Vernet D, Rajfer J, Gonzalez-Cadavid NF: Cloning of rat and human inducible penile nitric oxide synthase. Application for gene therapy of erectile dysfunction. Biol Reprod 1997;56:954-963.
19. Magee TR, Ferrini M, Garban HJ, Vernet D, Mitani K, Rajfer J, Gonzalez-Cadavid NF: Gene therapy of erectile dysfunction in the rat with penile neuronal nitric oxide synthase. Biol Reprod 2002;67:20-28.
20. Bivalacqua TJ, Champion HC, Abdel-Mageed AB, Kadowitz PJ, Hellstrom WJ: Gene transfer of prepro-calcitonin gene-related peptide restores erectile function in the aged rat. Biol Reprod 2001;65:1371-1377.
21. Shen Z-J, Wang H, Lu Y-L, Zhou X-L, Chen S-W, Chen Z-D: Gene transfer of vasoactive intestinal polypeptide into the penis improves erectile response in the diabetic rat. BJU Int 2005;95:890-894.
22. + (KCa) channel in cultured human corporal smooth muscle cells. J Urol 1995;153:818-825.
23. Christ GJ, Spray DC, Brink PR: Characterization of K currents in cultured human corporal smooth muscle cells. J Androl 1993;14:319-328.
24. Christ GJ, Wang HZ, Venkateswarlu K, Zhao W, Day NS: Ion channels and gap junctions: their role in erectile physiology, dysfunction, and future therapy. Mol Urol 1999;3:61-73.
25. Christ GJ, Rehman J, Day N, Salkoff L, Valcic M, Melman A, Geliebter J: Intracorporal injection of hSlo eDNA in rats produces physiologically relevant alterations in penile function. Am J Physiol 1998;275:H600-H608.
26. Nelson MT, Quayle JM: Physiological roles and properties of potassium channels in arterial smooth muscle. Am J Physiol 1995;268:C799-C822.
27. Christ GJ: Gene therapy treatments for erectile and bladder dysfunction. Curr Urol Rep 2004;5:52-60.
28. Melman A, Zhao W, Davies KP, Bakal R, Christ GJ: The successful long-term treatment of age related erectile dysfunction with hSlo eDNA in rats in vivo. J Urol 2003;170:285-290.
29. Melman A, Bar-Chama N, McCullough A, Davies K, Christ G: The first human trial for gene transfer therapy for the treatment of erectile dysfunction: preliminary results. Eur Urol 2005;48:314-318.
30. Christ GJ, Day N, Santizo C, Sato Y, Zhao W, Sclafani T, Bakal R, Salman M, Davies K, Melman A: Intracorporal injection of hSlo cDNA restores erectile capacity in STZ-diabetic F-344 rats in vivo. Am J Physiol Heart Circ Physiol 2004;287:H1544-H1553.